The speed of the development pipeline only adds to the challenge as GLP1 therapies are being used for approved indications beyond diabetes and obesity, including heart, liver and renal disease
Still, it should help relieve some of the hunger often experienced by people who reduce their calorie intake for weight loss
Both require the same careful technique
The next frontier is GLP-1 pills, and so far, it looks like Novo may have an early lead once again: In clinical trials, people on the pill version of Wegovy lost an average of 16.6% of their body weight after 64 weeks, compared to Eli Lillys GLP-1 pill, Foundayo, which helped patients lose 12.4% of their body weight after 72 weeks
The closer the two are in timing, the more the receptor signals overlap, and the larger the combined release
R., Chu, D., Okubo, T., Nagato, Y., & Yokogoshi, H